Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the USA

• Published in: Drug safety 2021-04, Vol.44 (4), p.479-497
• Main Authors: Weaver, James, Shoaibi, Azza, Truong, Huy Q., Larbi, Leila, Wu, Shujian, Wildgoose, Peter, Rao, Gowtham, Freedman, Amy, Wang, Lu, Yuan, Zhong, Barnathan, Elliot
• Format: Article
• Language: English
• Subjects: Anticoagulants; Bleeding; Clinical trials; Confidence intervals; Drug Safety and Pharmacovigilance; Exposure; Fibrillation; Heterogeneity; Indication; Medicine; Medicine & Public Health; NCT; NCT04394234; Original; Original Research Article; Patients; Pharmacology/Toxicology; Risk assessment; Statistical models; Thromboembolism; Uterus; Warfarin; Womens health
• ISSN: 0114-5916; 1179-1942
• DOI: 10.1007/s40264-021-01060-4

Background Antithrombotic therapies are associated with an increased bleeding risk. Abnormal uterine bleeding data have been reported in clinical trials of patients with venous thromboembolism (VTE), but data are limited for patients with atrial fibrillation (AF). Objective Using real-world data from four US healthcare databases (October 2010 to December 2018), we compared the occurrence of severe uterine bleeding among women newly exposed to rivaroxaban, apixaban, dabigatran, and warfarin stratified by indication. Methods To reduce potential confounding, patients in comparative cohorts were matched on propensity scores. Treatment effect estimates were generated using Cox proportional hazard models for each indication, in each database, and only for pairwise comparisons that met a priori study diagnostics. If estimates were homogeneous ( I 2 < 40%), a meta-analysis across databases was performed and pooled hazard ratios reported. Results Data from 363,919 women newly exposed to a direct oral anticoagulant or warfarin with a prior diagnosis of AF (60.8%) or VTE (39.2%) were analyzed. Overall incidence of severe uterine bleeding was low in the populations exposed to direct oral anticoagulants, although relatively higher in the younger VTE population vs the AF population (unadjusted incidence rates: 2.8–33.7 vs 1.9–10.0 events/1000 person-years). In the propensity score-matched AF population, a suggestive, moderately increased risk of severe uterine bleeding was observed for rivaroxaban relative to warfarin [hazard ratios and 95% confidence intervals from 0.83 (0.27–2.48) to 2.84 (1.32–6.23) across databases with significant heterogeneity], apixaban [pooled hazard ratio 1.45 (0.91–2.28)], and dabigatran [2.12 (1.01–4.43)], which were sensitive to the time-at-risk period. In the propensity score-matched VTE population, a consistent increased risk of severe uterine bleeding was observed for rivaroxaban relative to warfarin [2.03 (1.19–3.27)] and apixaban [2.25 (1.45–3.41)], which were insensitive to the time-at-risk period. Conclusions For women who need antithrombotic therapy, personalized management strategies with careful evaluation of benefits and risks are required. ClinicalTrials.gov Registration NCT04394234; registered in May 2020.